New research suggests that people who stop using blockbuster weight-loss injections like semaglutide or tirzepatide can put back on shed pounds much more quickly than those who halt conventional diet and exercise plans.
Published data in a major medical journal points out that while overweight people frequently drop substantial amounts of their total mass while undergoing treatment, the weight comes back at an estimated rate of nearly a kilo each month once they quit.
"Individuals purchasing these medications should be informed of the danger of quick weight regain when the treatment is stopped," stated expert Dr. Susan Jebb.
Such speed of recovery implies a reversion to original mass in about a year and a half.
Weighing Approaches
The research, which reviewed 37 of studies involving over 9,000 of patients, compared the results of these new drugs with other pills.
Researchers emphasize that people who shed pounds through diet and exercise typically see a less rapid weight regain—perhaps 100 grams monthly—post-intervention.
Understanding the Rapid Rebound
Experts believe the way of the injections explains the amplified rebound.
The injections mimic a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Long-term administration of GLP-1 levels far above than normal may cause the system to produce less of its own natural GLP-1, and could diminish responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.
"Stopping of this medication leads to appetite is no longer kept in check, making binge eating far more likely."
An Ongoing Issue?
Medical guidelines recommend the injections for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.
A number of clinicians say that, considering the likelihood of relapse, the therapy might need to be ongoing.
This opinion is supported by drug manufacturers, who state that the findings "highlight the chronic character of excess weight," comparing it to managing diseases like hypertension.
User Accounts
Individuals who have discontinued the jabs explain a sudden return of appetite.
"I experienced something activating and I was suddenly ravenous," described a patient.
This challenge is exacerbated if individuals have not adopted permanent lifestyle or habit modifications during therapy.
Significant Use
Survey data suggest that a significant number of adults in the UK have tried these injections in the past year, with desire remaining high.
- Use is more common among women compared to males.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion obtain the medications through private prescriptions rather than public health services.
Finally, clinicians stress that while the jabs are powerful agents for weight loss, they are not a permanent solution and long-term success relies on combined behavioural support.
